| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Mesothelin (MSLN), a tumor-associated antigen. MSLN is a cell surface glycoprotein that is highly expressed in several cancers, including mesothelioma, ovarian cancer, pancreatic cancer, and lung adenocarcinoma. In normal tissues, MSLN expression is limited to the mesothelial cells lining the pleura, peritoneum, and pericardium. Anetumab is an anti-MSLN antibody. By binding to MSLN on cancer cells, Anetumab can be used to deliver cytotoxic payloads as part of antibody-drug conjugates (ADCs).
|
|---|---|
| ln Vitro |
In vitro, Anetumab binds to MSLN with high specificity. The antibody effectively targets MSLN-expressing tumor cells. When conjugated to cytotoxic agents, such as in Anetumab ravtansine, the antibody delivers the payload specifically to MSLN-positive cancer cells, resulting in targeted cell killing. Anetumab demonstrates potent binding to MSLN and can be used in various assay formats to detect and target MSLN-expressing cells.
|
| ln Vivo |
In vivo, Anetumab can be used to synthesize Anetumab ravtansine, an ADC for the treatment of malignant tumors. Anetumab ravtansine has been investigated in clinical trials for the treatment of mesothelioma and other MSLN-expressing cancers. The ADC delivers a potent cytotoxic payload specifically to MSLN-positive tumor cells, resulting in targeted tumor cell killing and reduced systemic toxicity.
|
| Enzyme Assay |
The in vitro receptor binding assay for Anetumab typically involves ELISA-based methods to measure the binding affinity of the antibody to recombinant human MSLN protein. MSLN is coated onto microplate wells, and varying concentrations of Anetumab are added, followed by detection with an anti-human IgG1 secondary antibody. The binding affinity is determined from the dose-response curve. Surface plasmon resonance (SPR) can also be used to measure the binding kinetics of Anetumab to MSLN.
|
| Cell Assay |
In vitro cellular assays for Anetumab are performed using MSLN-expressing tumor cell lines. Cells are incubated with varying concentrations of Anetumab to assess binding and internalization. For ADC studies, Anetumab is conjugated to a cytotoxic payload, and the resulting ADC is tested for its ability to inhibit tumor cell proliferation and induce cell death in MSLN-positive cells. The specificity of Anetumab for MSLN is confirmed by testing binding to MSLN-negative cell lines.
|
| Animal Protocol |
In vivo animal experiments for Anetumab are conducted in mouse xenograft models using MSLN-expressing human tumor cell lines. Immunocompromised mice bearing tumor xenografts are administered Anetumab ravtansine or other Anetumab-based ADCs via intravenous injection at various dose levels. Tumor growth inhibition is assessed by measuring tumor volumes over time. Survival rates and toxicity are also monitored.
|
| ADME/Pharmacokinetics |
Anetumab exhibits pharmacokinetic properties consistent with other human IgG1 monoclonal antibodies. Following intravenous administration, the antibody displays a typical biphasic elimination profile with a long terminal half-life, approximately 14-21 days. The volume of distribution is consistent with the vascular space, and clearance is primarily mediated by the reticuloendothelial system.
|
| Toxicity/Toxicokinetics |
In preclinical toxicology studies, Anetumab has demonstrated a favorable safety profile with no significant off-target toxicities reported. The antibody is well-tolerated in animal models at doses that achieve therapeutic efficacy. As an antibody targeting a tumor-associated antigen, the primary safety concern is the potential for on-target, off-tumor toxicity in normal tissues that express MSLN. However, MSLN expression in normal tissues is limited to mesothelial cells, which may reduce the risk of significant toxicity.
|
| References | |
| Additional Infomation |
Anetumab (Anti-MSLN Antibody) is an anti-mesothelin (MSLN) antibody. It has a molecular weight of 143.8 kDa and an IgG1 isotype. Anetumab can be used to synthesize Anetumab ravtansine, a MSLN-targeting ADC. Anetumab has been investigated for the research of malignant tumors. Anetumab is not approved by any regulatory authority and is intended for research purposes only. The antibody is produced in CHO cells, purified by AKTA, and should be stored under recommended conditions.
|
| CAS # |
1954758-84-9
|
|---|---|
| Appearance |
Colorless to light yellow liquid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
